Introduction
Background
The local context
Aims
Methods
Study population
Data source
Variables
Statistical procedures
Ethics approval
Results
Demography
Male | Female | All | ||||
---|---|---|---|---|---|---|
n | % | n | % | n | % | |
Age | ||||||
0- < 5 yrs | 154 | 3.75 | 158 | 3.85 | 312 | 7.6 |
5- < 10 yrs | 118 | 2.87 | 119 | 2.9 | 237 | 5.77 |
10- < 15 yrs | 110 | 2.68 | 64 | 1.56 | 174 | 4.24 |
15- < 20 yrs | 344 | 8.38 | 92 | 2.24 | 436 | 10.62 |
20- < 25 yrs | 655 | 15.95 | 134 | 3.26 | 789 | 19.21 |
25- < 30 yrs | 601 | 14.63 | 164 | 3.99 | 765 | 18.63 |
30- < 35 yrs | 424 | 10.32 | 124 | 3.02 | 548 | 13.34 |
35- < 40 yrs | 249 | 6.06 | 95 | 2.31 | 344 | 8.38 |
40- < 45 yrs | 154 | 3.75 | 48 | 1.17 | 202 | 4.92 |
45- < 50 yrs | 113 | 2.75 | 32 | 0.78 | 145 | 3.53 |
50- < 55 yrs | 42 | 1.02 | 25 | 0.61 | 67 | 1.63 |
55- < 60 yrs | 17 | 0.41 | 20 | 0.49 | 37 | 0.9 |
60- < 65 yrs | 9 | 0.22 | 11 | 0.27 | 20 | 0.49 |
> 65 yrs | 14 | 0.34 | 17 | 0.41 | 31 | 0.75 |
Sum | 3004 | 73.14 | 1103 | 26.86 | 4107 | 100 |
Country of origin | ||||||
Syria | 1461 | 35.57 | 496 | 12.08 | 1957 | 47.65 |
Afghanistan | 244 | 5.94 | 110 | 2.68 | 354 | 8.62 |
Iran | 115 | 2.8 | 65 | 1.58 | 180 | 4.38 |
Somalia | 109 | 2.65 | 64 | 1.56 | 173 | 4.21 |
Benin | 141 | 3.43 | 27 | 0.66 | 168 | 4.09 |
India | 88 | 2.14 | 33 | 0.8 | 121 | 2.95 |
Guinea-Bissau | 101 | 2.46 | 15 | 0.37 | 116 | 2.82 |
Niger | 94 | 2.29 | 7 | 0.17 | 101 | 2.46 |
Russian Federation | 49 | 1.19 | 49 | 1.19 | 98 | 2.39 |
Iraq | 61 | 1.49 | 35 | 0.85 | 96 | 2.34 |
Unknown/missing | 26 | 0.63 | 11 | 0.27 | 37 | 0.9 |
Others | 515 | 12.54 | 191 | 4.65 | 706 | 17.19 |
Sum | 3004 | 73.14 | 1103 | 26.86 | 4107 | 100 |
Time under observation | ||||||
Less than 30 days | 249 | 6.06 | 125 | 3.04 | 374 | 9.11 |
31-60 days | 591 | 14.39 | 300 | 7.3 | 891 | 21.69 |
61–90 days | 375 | 9.13 | 139 | 3.38 | 514 | 12.52 |
91–120 days | 467 | 11.37 | 103 | 2.51 | 570 | 13.88 |
121–180 days | 360 | 8.77 | 45 | 1.1 | 405 | 9.86 |
181–240 days | 137 | 3.34 | 47 | 1.14 | 184 | 4.48 |
241–300 days | 132 | 3.21 | 47 | 1.14 | 179 | 4.36 |
More than 300 days | 693 | 16.87 | 297 | 7.23 | 990 | 24.11 |
Sum | 3004 | 73.14 | 1103 | 26.84 | 4107 | 100 |
Frequency of outpatient care
Diagnoses in outpatient care
Diagnosis groups | One-year prevalence | ||
---|---|---|---|
Chapter ICD-10 | % of men [95%-CI] | % of women [95%-CI] | % of all [95%-CI] |
1: Certain infectious and parasitic diseases | 19.1 [17.0–21.6] | 28.0 [23.9–32.6] | 21.6 [19.6–23.7] |
2: Neoplasms | 2.6 [1.9–3.6] | 10.9 [8.4–14.1] | 4.9 [4.0–6.0] |
3: Diseases of the blood, blood-forming organs and certain disorders inv. the immune mechanism | 2.2 [1.5–3.2] | 12.0 [9.4–15.4] | 4.8 [3.9–6.0] |
4: Endocrine, nutritional and metabolic diseases | 5.4 [4.2–6.8] | 17.9 [14.6–21.8] | 8.7 [7.5–10.2] |
5: Mental and behavioural disorders | 11.8 [10.1–13.7] | 21.1 [17.6–25.1] | 14.2 [12.7–16.0] |
6: Diseases of the nervous system | 7.2 [5.9–8.8] | 10.8 [8.3–14.0] | 8.1 [6.9–9.6] |
7: Diseases of the eye and adnexa | 9.8 [8.2–11.6] | 14.2 [11.2–17.9] | 11.0 [9.6–12.7] |
8: Diseases of the ear and mastoid process | 4.4 [3.4–5.7] | 8.8 [6.4–11.9] | 5.6 [4.6–6.9] |
9: Diseases of the circulatory system | 5.2 [4.2–6.6] | 12.0 [9.2–15.4] | 7.1 [6.0–8.5] |
10: Diseases of the respiratory system | 24.5 [22.2–27.1] | 36.1 [31.9–40.8] | 27.6 [25.5–29.8] |
11: Diseases of the digestive system | 16.9 [14.8–19.3] | 24.2 [20.6–28.4] | 18.8 [17.0–20.8] |
12: Diseases of the skin and subcutaneous tissue | 14.9 [13.1–17.0] | 25.3 [21.5–29.7] | 17.7 [15.9–19.6] |
13: Diseases of the musculoskeletal system and connective tissue | 21.0 [18.8–23.5] | 24.8 [21.2–29.0] | 22.0 [20.0–24.0] |
14: Diseases of the genitourinary system | 7.7 [6.3–9.3] | 39.9 [35.5–44.6] | 16.0 [14.3–17.8] |
15: Pregnancy, childbirth and the puerperium | – | 15.9 [13.0–19.5] | 4.2 [3.4–5.3] |
16: Certain conditions originating in the perinatal period | 0.3 [0.1–0.5] | 0.4 [0.1–1.1] | 0.3 [0.2–0.5] |
17: Congenital malformations, deformations and chromosomal abnormalities | 2.2 [1.5–3.3] | 4.7 [3.1–7.0] | 2.9 [2.2–3.8] |
18: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | 27.9 [25.4–30.6] | 54.6 [49.8–59.5] | 34.9 [32.5–37.3] |
19: Injury, poisoning and certain other consequences of external causes | 16.6 [14.5–18.9] | 13.0 [10.1–16.5] | 15.6 [13.9–17.5] |
20: External causes of morbidity and mortality | 0.3 [0.1–0.9] | 0.3 [0.0–2.3] | 0.3 [0.1–0.8] |
21: Factors influencing health status and contact with health services | 12.2 [10.5–14.2] | 52.4 [47.6–57.4] | 22.7 [20.7–24.8] |
22: Codes for special purposes | 6.8 [5.5–8.5] | 15.0 [12.1–18.6] | 8.9 [7.6–10.3] |
Prescriptions
Prescribed drugs | Proportion | One-year prevalence | |||
---|---|---|---|---|---|
Code | Group name | % of all prescriptions | % of men [95%-CI] | % of women [95%-CI] | % of all [95%-CI] |
M01 | Anti-inflammatory and antirheumatic products | 15.9 | 33.2 [30.5–36.1] | 41.1 [36.5–46.0] | 35.3 [33.0–37.8] |
J01 | Antibacterials for systemic use | 7.0 | 14.6 [12.7–16.7] | 28.5 [24.5–33.1] | 18.3 [16.5–20.3] |
N02 | Analgesics | 6.3 | 14.0 [12.1–16.1] | 25.0 [21.1–29.5] | 17.1 [15.3–19.1] |
A02 | Drugs for acid related disorders | 6.3 | 14.6 [12.6–16.8] | 16.2 [13.2–19.8] | 14.9 [13.3–16.7] |
R05 | Cough and cold preparations | 5.7 | 7.2 [6.0–8.7] | 14.2 [11.3–17.7] | 9.1 [7.9–10.5] |
R01 | Nasal preparations | 5.6 | 7.2 [5.9–8.9] | 16.2 [13.2–19.8] | 9.6 [8.3–11.1] |
N06 | Psychoanaleptics | 4.6 | 3.8 [2.9–5.0] | 7.8 [5.6–10.8] | 4.9 [3.9–6.1] |
N05 | Psycholeptics | 4.5 | 2.6 [1.8–3.6] | 6.3 [4.3–9.2] | 3.6 [2.8–4.7] |
J04 | Antimycobacterials | 3.1 | 1.6 [1.0–2.5] | 1.2 [0.6–2.5] | 1.5 [1.0–2.2] |
D07 | Corticosteroids, dermatological preparations | 3.1 | 7.0 [5.7–8.7] | 10.8 [8.1–14.2] | 8.1 [6.8–9.5] |
J07 | Vaccines | 2.6 | 3.8 [2.8–5.2] | 8.4 [6.0–11.7] | 5.1 [4.1–6.4) |